All the news Showing 10 of 217 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NHS England seeks drug price cuts to eliminate hepatitis C by 2025 Keith Alcorn / 30 January 2018 NHS England announced this week that it aims to eliminate hepatitis C by 2025 – if it can negotiate 'best value for money' deals with the pharmaceutical industry in a new round ... India to launch national program to control viral hepatitis and aims to negotiate lower drug prices Pharma Letter / 09 January 2018 Hepatitis C: In Argentina INPI rejected a key patent on Sofosbuvir Fundación Grupo Efecto Positivo / 05 December 2017 Gilead prices hepatitis C giant Sovaldi in China at one-fifth the US price: report FiercePharma / 29 November 2017 Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing Medicines Law & Policy / 27 November 2017 Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics TAG / 01 November 2017 Gilead HCV drug sales down in 2017 third quarter compared with 2016 Healio / 31 October 2017 Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty Intellectual Property Watch / 26 October 2017 Merck targets high-risk military veterans for hepatitis C lessons Fierce Pharma / 16 October 2017 UK pharma denied legal challenge to drugs bill cap Pharmaphorum / 05 October 2017 ← Prev1...34567...22Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive